We are live on ! Find out more
ARLZ

Aralez Pharmaceuticals Inc.
ARLZ

Delisted

ARLZ was delisted on the 20th of August, 2018.

Back to rankings

4 hedge funds and large institutions have $1K invested in Aralez Pharmaceuticals Inc. in 2018 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 0 increasing their positions, 1 reducing their positions, and 46 closing their positions.

New
Increased
Maintained
Reduced
Closed

92% less funds holding

Funds holding: 48 → 4 (-44)

96% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 46

100% less capital invested

Capital invested by funds: $1.8M → $1K (-$1.8M)

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 1

Holders
4
Holders Change
-44
Holders Change %
-91.67%
% of All Funds
0.09%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
–
Reduced
1
Closed
46
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
AA
Ancora Advisors
Ohio
+$2.14K
2
Simplex Trading
Simplex Trading
Illinois
+$102

Top Sellers

Rank Fund Capital Flow
1
DM
Deerfield Management
New York
-$576K
2
Wells Fargo
Wells Fargo
California
-$282K
3
SM
Salzhauer Michael
-$174K
4
PCM
PAR Capital Management
Massachusetts
-$168K
5
Renaissance Technologies
Renaissance Technologies
New York
-$109K
Name Holding Trade Value Shares
Change 		Change in
Stake
GT
1
Glenmede Trust
Pennsylvania
$1K -$4.09K -16,000 -27%
DM
2
Deerfield Management
New York
– -$576K -1,644,583 Closed
Wells Fargo
3
Wells Fargo
California
– -$282K -805,912 Closed
SM
4
Salzhauer Michael
– -$174K -497,897 Closed
PCM
5
PAR Capital Management
Massachusetts
– -$168K -481,400 Closed
Renaissance Technologies
6
Renaissance Technologies
New York
– -$109K -310,400 Closed
Deutsche Bank
7
Deutsche Bank
Germany
– -$99K -281,545 Closed
SCP
8
Silverleafe Capital Partners
Tennessee
– -$35K -100,000 Closed
FSA
9
Franklin Street Advisors
North Carolina
– -$34K -96,429 Closed
Macquarie Group
10
Macquarie Group
Australia
– -$24K -69,667 Closed
Goldman Sachs
11
Goldman Sachs
New York
– -$24K -68,301 Closed
Janney Montgomery Scott
12
Janney Montgomery Scott
Pennsylvania
– -$23K -65,500 Closed
Northern Trust
13
Northern Trust
Illinois
– -$20K -57,235 Closed
Millennium Management
14
Millennium Management
New York
– -$19K -54,807 Closed
Bank of New York Mellon
15
Bank of New York Mellon
New York
– -$19K -51,690 Closed
BP
16
Ballentine Partners
Massachusetts
– -$18K -50,000 Closed
Group One Trading
17
Group One Trading
Illinois
– -$16K -45,671 Closed
Morgan Stanley
18
Morgan Stanley
New York
– -$14K -41,977 Closed
JMPWA
19
JP Morgan Private Wealth Advisors
California
– -$14K -40,000 Closed
Susquehanna International Group
20
Susquehanna International Group
Pennsylvania
– -$14K -39,211 Closed
M&T Bank
21
M&T Bank
New York
– -$11K -30,000 Closed
SRC
22
Shufro Rose & Co
New York
– -$7K -20,987 Closed
NL
23
NWAM LLC
Washington
– -$7K -18,800 Closed
Citadel Advisors
24
Citadel Advisors
Florida
– -$6K -16,471 Closed
Squarepoint
25
Squarepoint
New York
– -$5K -15,700 Closed
1
2

ARLZ Hedge Fund Activity: Q3 2018 in Review

4 of the 4,375 institutional investors tracked by Wall St. Rank reported a position in Aralez Pharmaceuticals Inc. (ARLZ) for Q3 2018, worth a combined $1K — down 100% from $1.8M a quarter earlier.

Sellers outnumbered buyers: 46 funds closed out of ARLZ and 2 opened new positions — a net loss of 44 holders — while 1 trimmed existing stakes and 0 added.

The largest buyer was Ancora Advisors, opening a new position worth an estimated $2.14K. The largest seller was Deerfield Management, exiting entirely with an estimated $576K sold.

  • 4 institutional investors held Aralez Pharmaceuticals Inc. (ARLZ) as of Q3 2018, down from 48 in Q2 2018.
  • Funds reported $1K of Aralez Pharmaceuticals Inc. stock for Q3 2018, down 100% quarter-over-quarter.
  • 2 funds opened new Aralez Pharmaceuticals Inc. positions in Q3 2018 and 46 closed out, a net change of -44 holders.
  • The largest Aralez Pharmaceuticals Inc. buyer in Q3 2018 was Ancora Advisors, an estimated $2.14K added.
  • The largest Aralez Pharmaceuticals Inc. seller in Q3 2018 was Deerfield Management, an estimated $576K sold.

Based on aggregated 13F filings for Q3 2018.